The Rhinovirus Hospitalization and Investigation of Nasal-airway Omics (RHINO) Study

Summary

The goal of this study is to determine the burden of Rhinoviruses (RVs) as a cause of acute, severe, respiratory illnesses leading to hospitalization. A community cohort of 120 children between 12 and 36 months of age will be enrolled in the first year of the study and followed (when well and sick) for 36 months to identify the circulating RVs and provide samples to establish a host nasal transcriptome differentiating clinical from subclinical RV infections. A hospitalized cohort of 450 infants and children will be enrolled during years 1 through 3 of the study and followed for the duration of their hospitalization to investigate the findings of the community cohort. An additional 100 healthy children aged 5-17 years will be enrolled for age-match comparison with the older hospitalized cohort.

Conditions

• Rhinovirus

Interventions

DIAGNOSTIC_TEST

Nasal Swab Healthy Surveillance

Families will be asked to collect nasal swabs from their children during specified surveillance months (February, April, September, and December). Caregivers will be instructed to only collect surveillance samples during these months if and when children have been free of respiratory symptoms for at least two weeks prior to sampling. Caregiver surveys are part of quarterly surveillance.

DIAGNOSTIC_TEST

Nasal Swab Sick Samples

Caregivers will be instructed to watch for respiratory symptoms and collect nasal swabs 24-48 hours after symptom onset. Caregiver surveys are part of sick sample collection

DIAGNOSTIC_TEST

Nasal Swab Hospitalized Cohort

2 nasal swabs collected upon consent, one anterior and one mid-turbinate

OTHER

Sick Follow-up Survey

Caregivers are surveyed 7-13 days after sick sample collection

OTHER

Older Cohort Control Group

Participants will be enrolled as needed based on enrollment of hospitalized patients

Sponsors & Collaborators

• National Institute of Allergy and Infectious Diseases (NIAID)

  collaborator NIH

• University of Wisconsin, Madison

  lead OTHER

Principal Investigators

• Ellen R Wald, MD · UW School of Medicine and Public Health

Eligibility

Max Age

17 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2026-05-31

Primary Completion

2030-05-31

Completion

2030-05-31

Countries

• United States

Study Locations